Reported 25,399 shares, unchanged from the prior quarter.
Reported value 3.6%; share count 0.0% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2025-09-30 | 1237439 |
| 2025-12-31 | 332219 |
| 2026-03-31 | 453118 |
| 2026-06-30 | 467596 |
| 2026-09-30 | 484613 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q3 2026 | Unchanged | 25,399 | 0 (0.0%) | 0.32% | $484,613 | 2026-11-16 | |
| Q2 2026 | Unchanged | 25,399 | 0 (0.0%) | 0.26% | $467,596 | 2026-08-14 | |
| Q1 2026 | Unchanged | 25,399 | 0 (0.0%) | 0.29% | $453,118 | 2026-05-15 | |
| Q4 2025 | Unchanged | 25,399 | 0 (0.0%) | 0.15% | $332,219 | 2026-02-17 | |
| Q3 2025 | New | 25,399 | +25,399 (0.0%) | 0.69% | $1,237,439 | 2025-11-14 |
Who else reported the position
168 managers reported VOR BIOPHARMA INC for Q3 2026.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| FMR LLC | Added | 6,759,007 | +1,826,858 | < 0.01% | $128,961,854 | 5 qtrs |
| TCG Crossover Management LLC | Unchanged | 5,673,078 | 0 | 3.06% | $108,242,328 | 3 qtrs |
| RA CAPITAL MANAGEMENT L P | Added | 4,503,882 | +2,101,787 | 0.86% | $85,934,069 | 5 qtrs |
| FCPM III SERVICES B V | Reduced | 3,405,279 | -712,075 | 6.13% | $64,972,723 | 5 qtrs |
| BlackRock Inc | Reduced | 3,306,494 | -161,613 | < 0.01% | $63,087,906 | 5 qtrs |
| VR Adviser LLC | Unchanged | 3,041,719 | 0 | 2.82% | $58,035,999 | 5 qtrs |
| Frazier Life Sciences Management L P | Added | 2,743,939 | +200,000 | 1.3% | $52,354,356 | 4 qtrs |
| VANGUARD CAPITAL MANAGEMENT LLC | Reduced | 2,035,477 | -48,851 | < 0.01% | $38,836,901 | 3 qtrs |
| STATE STREET CORPORATION | Reduced | 1,969,801 | -646,535 | < 0.01% | $37,583,803 | 5 qtrs |
| Caligan Partners LP | Unchanged | 1,925,066 | 0 | 2.25% | $36,730,259 | 4 qtrs |
Filing details and methodology As reported
- Report period
- September 30, 2026
- Filed
- November 16, 2026
- Filing type
- 13F-HR
- Position type
- COM NEW
Voting authority reported
- Sole
- 25,399
- Shared
- 0
- None
- 0
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.